BioScrip

BioScrip® is a leading provider in comprehensive, cost-effective pharmaceutical and home care solutions. Our goal is to partner with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers to provide access to infusible medications and management solutions that optimize outcomes for chronic and other complex healthcare conditions. At BioScrip, our patients receive personalized, safe, effective and convenient infusion therapies to help improve quality of life. Our team of professionals assist each patient in every step of their office or home infusion experience.
Company Growth (employees)
Type
Public
HQ
Denver, US
Size (employees)
2,039 (est)+11%
BioScrip is headquartered in Denver, US

Key People at BioScrip

Richard M. Smith

Richard M. Smith

President & CEO

BioScrip Office Locations

BioScrip has offices in Denver, Eden Prairie and Elmsford
Denver, US (HQ)
950 1600 Broadway
Elmsford, US
100 Clearbrook Road
Eden Prairie, US
10050 Crosstown Circle

BioScrip Data and Metrics

BioScrip Financial Metrics

BioScrip's revenue was reported to be $935.6 m in FY, 2016 which is a 5% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

935.6 m

Revenue growth (FY, 2015 - FY, 2016), %

(5%)

Gross profit (FY, 2016)

265.6 m

Gross profit margin (FY, 2016), %

28%

Net income (FY, 2016)

(41.5 m)

Market capitalization (26-May-2017)

212.9 m

Closing share price (26-May-2017)

1.8

Cash (31-Dec-2016)

9.6 m

EV

655.3 m
BioScrip's current market capitalization is $212.9 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

842.2 m984.1 m982.2 m935.6 m

Revenue growth, %

17%(0%)(5%)

Cost of goods sold

721.3 m670 m

Gross profit

271.8 m261.1 m260.9 m265.6 m

Gross profit Margin, %

32%27%27%28%

Operating expense total

166 m

EBIT

(7 m)(91.1 m)(287.6 m)

EBIT margin, %

(1%)(9%)(29%)

Interest expense

37.3 m38.2 m

Interest income

37.3 m

Income tax expense

(21.5 m)2 m

Net Income

(69.7 m)(147.5 m)(299.7 m)(41.5 m)
Numbers are in $, USDFY, 2015FY, 2016

Cash

15.6 m9.6 m

Accounts Receivable

Inventories

20 m18.5 m

Current Assets

187 m176.1 m

PP&E

31.9 m32.5 m

Goodwill

308.7 m365.9 m

Total Assets

546.5 m607.7 m

Accounts Payable

65.1 m59.1 m

Total Debt

434 m451.9 m

Current Liabilities

156 m130.4 m

Additional Paid-in Capital

531.8 m611.8 m

Retained Earnings

(601.9 m)(643.4 m)

Debt to Assets Ratio

0.8 x0.7 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(299.7 m)(41.5 m)

Depreciation and Amortization

22.7 m21.6 m

Accounts Receivable

Inventories

(5.8 m)10 m

Accounts Payable

(24.1 m)(20.5 m)

Cash From Operating Activities

(61.1 m)(261 k)(64.7 m)(42.8 m)

Cash From Investing Activities

13 m(73 m)

Cash From Financing Activities

66.6 m109.7 m

Interest Paid

34.3 m34.7 m
Y, 2016

EV/CFO

-15.3 x

Debt/Assets

0.7 x

BioScrip Market Value History

BioScrip Online and Social Media Presence

BioScrip News and Updates

BioScrip Company Life and Culture

You may also be interested in